Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q3 2021 · 10-Q
Revenue$489.00K$489.00K— vs Q3 2020 Net Income-$4.23M-$4.23MN/M vs Q3 2020 EPS Diluted-$0.25-$0.25N/M vs Q3 2020 Operating Income-$4,232,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-865.4%
Net margin-865.0%
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end